- Citi’s 17th Annual
BioPharma Conference - Taking place in-person in
Boston onSeptember 8 th
- Taking place in-person in
H.C. Wainwright 24th AnnualGlobal Investment Conference - Company Presentation:
September 12 th at12:30pm ET inNew York City
- Company Presentation:
Ladenburg Thalmann Healthcare Conference 2022- Company Presentation:
September 29 th at4:00pm ET inNew York City
- Company Presentation:
An audio webcast link for select events, when available, will be posted to Bionomics’ website in the Events and Presentations page of the Investors section.
Released on authority of the Executive Chairman.
FOR FURTHER INFORMATION PLEASE CONTACT:
Investor Relations Mr. Vice President, Strategy and Corporate Development +1 (650) 524-5143 cbernstein@bionomics.com.au | Investor Relations kgardner@lifesciadvisors.com |
About
Bionomics (ASX:BNO, NASDAQ:BNOX) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside
www.bionomics.com.au
Source:
2022 GlobeNewswire, Inc., source